Sometimes a clinical trial result is so good it makes a stock jump. And sometimes it makes it soar. Kodiak Sciences Inc. (KOD) is having the latter kind of day, with shares up a blistering 52% and hitting a fresh 52-week high after the biotech dropped what can only be described as spectacular Phase 3 data for its eye drug.

The catalyst? Positive topline results from the GLOW2 study for Zenkuda (tarcocimab tedromer) in treating diabetic retinopathy. For the uninitiated, that's a serious eye complication of diabetes where high blood sugar damages the retina's blood vessels, leading to leakage, bleeding, and potential vision loss. It's a huge market, and an effective treatment is a big deal.

The numbers from the trial are the kind that make biotech investors' hearts beat faster. Zenkuda demonstrated that 62.5% of patients achieved a ≥2-step improvement on the Diabetic Retinopathy Severity Scale. The sham (placebo) group? A mere 3.3%. That's not just a win; it's a rout. The statistical significance is, as they say in the biz, strong.

But wait, there's more. The drug also showed an 85% reduction in the risk of developing sight-threatening complications (2.4% on the drug vs. 15.8% on sham). And for a ≥3-step improvement—a deeper level of recovery—Zenkuda posted 13.7% versus a big, fat 0% for the placebo. The drug was also reported to be well-tolerated, with low rates of ocular adverse events. In short: it worked, it worked well, and it didn't cause major new problems. That's the trifecta.

"We are excited about our multi-indication BLA-ready profile," said CEO Victor Perlroth, hinting at the company's broader pipeline beyond this single study. The patient population was diverse, including those with more severe forms of the disease, and the company is now reportedly advancing its plans to submit a Biologics License Application (BLA) to regulators. Translation: they're getting their paperwork ready to ask for official approval to sell this thing.

Now, let's talk about the stock, because the move has been nothing short of explosive. At the time of publication, shares were up 52.22% at $34.63. That's a new 52-week high. For some technical context: the stock is currently trading 45.5% above its 20-day simple moving average and 47.5% above its 100-day average. That's what you call strong short-term momentum. Zoom out, and the picture is even wilder: over the past 12 months, shares are up a mind-bending 1,086.88%.

But is it too hot to handle? The Relative Strength Index (RSI) sits at 42.81, which is considered neutral territory—suggesting the stock isn't overbought or oversold right now. However, the MACD indicator is at -0.8342, below its signal line, which technical analysts read as a bearish signal indicating some selling pressure. So you have neutral RSI and bearish MACD giving mixed messages on the momentum front. Key resistance is seen at $40, with support down at $30.

What do the professionals think? The analyst consensus sits at a Hold rating with an average price target of $15.71, which looks almost comically conservative given today's price action. But recent moves tell a more bullish story: HC Wainwright & Co. maintains a Buy with a $38 target (from February), and UBS initiated coverage with a Buy and a $50 price target back in January. Someone believes.

So there you have it. A biotech stock rockets on phenomenal clinical data, plans a major regulatory push, and leaves a trail of impressive statistics and split technical indicators in its wake. For investors in Kodiak, it's been a very good day. The question now is whether the glow from GLOW2 can last.